Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases

Health Quest System, Sharon Hospital, Sharon, CT 06069, USA
Antibiotics 2019, 8(2), 72;
Published: 30 May 2019
(This article belongs to the Special Issue Antibiotics Resistance of Borrelia)


PDF [248 KB, uploaded 30 May 2019]



Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6–23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram. View Full-Text

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material



Please notice this is by Dr. Ken Liegner, an experienced Lyme literate doctor affiliated with ILADS.  The IDSA/NIH/CDC people are not doing work like this.  They are fixated on the acute phase leaving chronically infected people out to dry.

Thankfully, some good work is being done in the treatment area.  Some examples:  I mention disulfiram in the comment section.  I mention disulfiram in the comment section. Within this article is a link to an ILADS video Dr. Burrascano made recently. I highlight his video and explain his findings within his own practice of what worked for many patients, including a “cycling” approach to treatment as well as the fact blood levels of antibiotics are different for people. This treatment points are important because if the blood level isn’t high enough, pathogens will not be killed with a potential for them to mutate and become stronger in the future.


Be encouraged.  There’s some great stuff in the works.



%d bloggers like this: